NasdaqGS:ERASBiotechs
Do Early ERAS-0015 Data Reframe Erasca’s (ERAS) Ambitions in RAS-Targeted Oncology?
Erasca recently reported encouraging early Phase 1 AURORAS-1 data for its pan-RAS molecular glue degrader ERAS-0015, showing multiple partial responses across RAS-mutated tumor types with a clean safety profile and linear pharmacokinetics, while ERAS-4001 continued dose escalation in the BOREALIS-1 trial.
What makes this update particularly interesting is that meaningful anti-tumor activity emerged at a relatively low 8 mg once-daily dose, potentially widening the drug’s future dosing window...